ATH-1018 / Athira Pharma - LARVOL DELTA

Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire) - "Athira Pharma, Inc...announced the presentation of preclinical data on two small molecule positive modulators of the HGF/MET signaling pathway, ATH-1018 and ATH-1019, at the 2022 Peripheral Nerve Society (PNS) Annual Meeting. The research highlights the effect of ATH-1018 and ATH-1019 on neuropathic pain-related behaviors in a preclinical model of streptozotocin (STZ)-induced diabetic neuropathy. Data demonstrate that measures of pain-related behaviors were significantly improved on testing days across all dose levels for each molecule. Pain-related behaviors were also significantly reduced prior to dosing on day 25 when ATH-1018 or ATH-1019 had been cleared from plasma, suggestive of potentially persistent pain-modifying effects."

Preclinical • CNS Disorders • Diabetic Neuropathy • Neuralgia • Pain • Peripheral Neuropathic Pain